Literature DB >> 17707122

PINK1 mutants associated with recessive Parkinson's disease are defective in inhibiting mitochondrial release of cytochrome c.

Hung-Li Wang1, An-Hsun Chou, Tu-Hsueh Yeh, Allen H Li, Ying-Ling Chen, Yu-Li Kuo, Shu-Ru Tsai, Szu-Tzu Yu.   

Abstract

Mutations in PTEN-induced kinase 1 (PINK1) gene cause recessive familial type 6 of Parkinson's disease (PARK6). We investigated molecular mechanisms underlying PINK1 neuroprotective function and PARK6 mutation-induced loss of PINK1 function. Overexpression of wild-type PINK1 blocked mitochondrial release of apoptogenic cytochrome c, caspase-3 activation and apoptotic cell death induced by proteasome inhibitor MG132. N-terminal truncated PINK1 (NDelta35), which lacks mitochondrial localization sequence, did not block MG132-induced cytochrome c release and cytotoxicity. Despite mitochondrial expression, PARK6 mutant (E240K), (H271Q), (G309D), (L347P), (E417G) and C-terminal truncated (CDelta145) PINK1 failed to inhibit MG132-induced cytochrome c release and caspase-3 activation. Overexpression of wild-type PINK1 blocked cytochrome c release and cell death caused by atractyloside, which opens mitochondrial permeability transition pore (mPTP). PARK6 PINK1 mutants failed to inhibit atractyloside-induced cytochrome c release. These results suggest that PINK1 exerts anti-apoptotic effect by inhibiting the opening of mPTP and that PARK6 mutant PINK1 loses its ability to prevent mPTP opening and cytochrome c release.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17707122     DOI: 10.1016/j.nbd.2007.07.010

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  40 in total

1.  Mitochondrially localized PKA reverses mitochondrial pathology and dysfunction in a cellular model of Parkinson's disease.

Authors:  R K Dagda; A M Gusdon; I Pien; S Strack; S Green; C Li; B Van Houten; S J Cherra; C T Chu
Journal:  Cell Death Differ       Date:  2011-06-03       Impact factor: 15.828

Review 2.  Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis.

Authors:  Rebecca Banerjee; Anatoly A Starkov; M Flint Beal; Bobby Thomas
Journal:  Biochim Biophys Acta       Date:  2008-11-14

3.  PINK1 and its familial Parkinson's disease-associated mutation regulate brain vascular endothelial inflammation.

Authors:  Wang Yunfu; Liu Guangjian; Zhong Ping; Sun Yanpeng; Fang Xiaoxia; Hu Wei; Yuan Jiang; Hu Jingquan; Wang Songlin; Zhang Hongyan; Liu Yong; Chen Shi
Journal:  J Mol Neurosci       Date:  2014-01-03       Impact factor: 3.444

4.  A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1.

Authors:  Nicholas T Hertz; Amandine Berthet; Martin L Sos; Kurt S Thorn; Al L Burlingame; Ken Nakamura; Kevan M Shokat
Journal:  Cell       Date:  2013-08-15       Impact factor: 41.582

Review 5.  Gene therapy targeting mitochondrial pathway in Parkinson's disease.

Authors:  Chi-Jing Choong; Hideki Mochizuki
Journal:  J Neural Transm (Vienna)       Date:  2016-09-16       Impact factor: 3.575

Review 6.  Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models.

Authors:  Ruben K Dagda; Jianhui Zhu; Charleen T Chu
Journal:  Mitochondrion       Date:  2009-06-27       Impact factor: 4.160

Review 7.  Mitochondrial respiratory dysfunction and mutations in mitochondrial DNA in PINK1 familial parkinsonism.

Authors:  Sergio Papa; Anna Maria Sardanelli; Nazzareno Capitanio; Claudia Piccoli
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

Review 8.  Programmed cell death in Parkinson's disease.

Authors:  Katerina Venderova; David S Park
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

Review 9.  The mitochondrial kinase PINK1, stress response and Parkinson's disease.

Authors:  Marina Jendrach; Suzana Gispert; Filomena Ricciardi; Michael Klinkenberg; Rudolf Schemm; Georg Auburger
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

10.  Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle.

Authors:  Kristen A Malkus; Elpida Tsika; Harry Ischiropoulos
Journal:  Mol Neurodegener       Date:  2009-06-05       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.